Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)Yuankai Shi, Luyao Sun, Lin Wu et al.|癌症：英文版|2022Cited by 60
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapyFengying Wu, Tao Jiang, Gongyan Chen et al.|癌症：英文版|2022Cited by 20
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera <sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trialYuankai Shi, Yanan Ji, Lin Gui et al.|Hematological Oncology|2022Cited by 9
Identification of macrophage-related genes correlated with prognosis and immunotherapy efficacy in non-small cell lung cancerShaodi Wen, Bo Shen, Renrui Zou et al.|Heliyon|2024Cited by 7